Strategic Landscape

The RNA M&A Window Has Opened

Three major acquisitions totaling ~$15B in the last 18 months validate mixmer ASO chemistry, miRNA targeting, and muscle/cardiac delivery.

Cardior
$1.1B (Novo Nordisk)
  • Cardiac miRNA (miR-132)
  • LNA mixmer chemistry
Regulus
$1.7B (Novartis)
  • Kidney miRNA (miR-17)
  • 2'-MOE mixmer chemistry
Avidity
$12B (Novartis)
  • Muscle/cardiac AOCs
  • DMD + cardiac programs
  • PMO chemistry
  • LNA mixmers de-risked by Cardior (Novo Nordisk), Santaris (Roche), miRagen
  • Cardiac + muscle delivery commanded premium valuation (Avidity–Novartis)
  • 2026–2029 positioned as the next strategic acquisition window
The features defining these billion-dollar transactions—mixmer chemistry, reliable delivery to heart and muscle, true systemic reach—are the key strengths of Elenae’s scalable platform.
Problem

Proven Markets, But Delivery Remains the Challenge

Despite proven success, today’s RNA medicine delivery platforms remain limited, complex, and costly.

Liver-Focused RNA Platforms
(GalNAc-siRNA, LNP-siRNA, Gapmer ASOs)

  • ✓ Hepatic targets validated
  • ✗ Formulation complexity (LNPs)
  • ✗ Limited extrahepatic distribution
  • ✗ Hepatotoxicity and nephrotoxicity risks

Antibody-Oligonucleotide Conjugates
(AOCs)

  • ✓ Muscle/cardiac access
  • ✗ Multi-component (antibody + linker + oligo) = high COGS
  • ✗ Complex biologics manufacturing
  • ✗ Weak ASO chemistry (PMO)
  • ✗ Receptor-dependent delivery

Elenae’s LNA mixmers deliver naked, in saline, to multiple organs—no formulation, no conjugate, no receptor dependency.

Platform

A Steric-Block Chemistry That
Reaches Beyond the Liver

LNA ASO mixmers use a steric-blocking mechanism with no RISC loading and no RNase H cleavage. The ASO binds its target RNA through high-affinity LNA base-pairing and physically blocks biological processes without cutting the RNA.

Steric-Block Mechanism

No cleavage-associated toxicity. Enables exon skipping, splice modulation, miRNA inhibition, and translational regulation from a single chemistry.

Native Distribution

Heart, muscle, lung, retina, kidney, liver, and adipose reached after SC dosing in saline. No LNP, no GalNAc, no antibody conjugate required.

Chronic Safety

24-week NHP chronic dosing at 5 mg/kg/week SC. No hepatotoxicity, nephrotoxicity, immune activation, or injection site reactions across three species.

AI-Guided Design

Dual engines for miRNA targeting and exon skipping. 15 years of proprietary parameter libraries. Target-to-candidate in weeks. Iterative optimization from experimental data.

Tissue Distribution

Validated Multi-Organ Engagement

After a single subcutaneous dose of naked ASO in saline, LNA mixmers distribute broadly across major organs. Intrinsic to the chemistry, not engineered per-tissue. Compatible with conjugation strategies when tissue-restricted delivery is desired.

Heart
>95%
Mouse, Pig, NHP
Skeletal Muscle
>95%
Mouse, Pig, NHP
Lung
>95%
Mouse, NHP
Retina
Confirmed
Mouse, NHP
Kidney
>95%
Mouse, NHP
Liver
>95%
Mouse, NHP

Target engagement measured by miR-128-3p knockdown. Distribution intrinsic to LNA mixmer chemistry.

Mouse tissue distribution
Near-complete miR-128 knockdown in liver, heart, lung, kidney, and muscle after single SC dose in saline. Includes LNA mixmer mechanism diagram (steric blocking of target RNA).